QNTM

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

Dollar change -0.46
Percentage change -13.29	%

Peers: JNJ PFE MRK BMY LLY GILD REGN AMGN BIIB VRTX

| Held by: PSIL

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-14.87	Insider Own	17.20%	Shs Outstand	1.86M	Perf Week	-26.11%
Market Cap	5.76M	Forward P/E	-	EPS next Y	-1.54	Insider Trans	0.00%	Shs Float	1.59M	Perf Month	-40.36%
Income	-10.49M	PEG	-	EPS next Q	-0.80	Inst Own	2.50%	Short Float	0.38%	Perf Quarter	-25.93%
Sales	0.00M	P/S	-	EPS this Y	89.06%	Inst Trans	152.22%	Short Ratio	0.06	Perf Half Y	-74.94%
Book/sh	8.74	P/B	0.34	EPS next Y	52.91%	ROA	-55.28%	Short Interest	0.01M	Perf Year	-95.17%
Cash/sh	3.44	P/C	0.87	EPS next 5Y	-	ROE	-67.43%	52W Range	3.15 - 70.85	Perf YTD	-94.98%
Dividend Est.	-	P/FCF	-	EPS past 5Y	31.10%	ROI	-64.42%	52W High	-95.77%	Beta	0.61
Dividend TTM	-	Quick Ratio	3.76	Sales past 5Y	0.00%	Gross Margin	-	52W Low	-4.76%	ATR (14)	0.69
Dividend Ex-Date	-	Current Ratio	3.76	EPS Y/Y TTM	60.85%	Oper. Margin	-	RSI (14)	25.37	Volatility	30.58% 16.71%
Employees	-	Debt/Eq	0.02	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	12.80
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	-122.28%	Payout	-	Rel Volume	10.25	Prev Close	3.46
Sales Surprise	-	EPS Surprise	0.00%	Sales Q/Q	-	Earnings	Nov 13	Avg Volume	98.61K	Price	3.00
SMA20	-30.13%	SMA50	-39.07%	SMA200	-79.49%	Trades		Volume	1,010,485	Change	-13.29%

Dec-20-24 07:30PM	Quantum Biopharma Announces Closing of Second Tranche (ACCESSWIRE) -13.29%
09:15AM	Quantum Biopharma Diversifies Treasury With the Purchase of USD $1,000,000 of Bitcoin (BTC) and Other Cryptocurrencies and to Allow for Future Financings and Other Transactions in Cryptocurrency (ACCESSWIRE)
Dec-13-24 07:00PM	Quantum Biopharma Announces Closing of First Tranche (ACCESSWIRE)
Dec-10-24 07:30AM	Quantum Biopharma Announces That the Safety Review Committee Recommends Commencing Dosing of Second Cohort in the Phase 1 Multiple Ascending Dose Clinical Trial for Lucid-21-302 (Lucid-MS) (ACCESSWIRE)
Dec-05-24 07:30AM	Quantum Biopharma Announces Non-Brokered Private Placement of Convertible Debenture Units for Gross Proceeds of Up to $5 Million (ACCESSWIRE)
07:00AM	Loading…
Nov-25-24 07:00AM	Quantum BioPharma Previously Known as FSD Pharma (Nasdaq:HUGE) (CSE:HUGE) Invites Shareholders to Come Forward and Join Hands With the Company in the US700M$+ Court Case the Company Has Filed Against CIBC, RBC, and Others for Alleged Spoofing/Stock Price Manipulation (ACCESSWIRE)
Oct-29-24 07:30AM	Quantum Biopharma Announces that Sentinel Dosing has Started for the Phase-1 Multiple Ascending Dose Clinical Trial for Lucid-21-302 (Lucid-Ms) in Australia (ACCESSWIRE)
Oct-28-24 11:10AM	Christian Attar Files Market Manipulation Case On Behalf of Quantum Biopharma (PR Newswire)
Oct-23-24 09:30AM	Freedman Normand Friedland Files Market Manipulation Case On Behalf of Quantum Biopharma (PR Newswire) +15.45%
Oct-22-24 07:00AM	Quantum Biopharma (NASDAQ:QNTM) Posts Link on Its Website to Access the Filed Complaint Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofing (ACCESSWIRE) -17.33%
Oct-21-24 11:55AM	Quantum BioPharma Ltd. Alleges Market Manipulation, Files Lawsuit, unbuzzed Continues To Gain Traction (News Direct) -9.80%
05:30AM	Quantum BioPharma Files a US Federal Lawsuit Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofing (Newsfile)
07:00AM	Quantum BioPharma (Nasdaq: QNTM) Files a US Federal Lawsuit Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofing (ACCESSWIRE)
Oct-15-24 06:00AM	Quantum BioPharma Ltd. (NASDAQ: QNTM): Pioneering Alcohol Metabolism Support with Unbuzzd (News Direct)
Oct-07-24 08:40AM	Quantum BioPharma Ltd. Provides Update from Celly Nutrition Signing a Master Distribution Agreement with FUSION Distribution Group across Puerto Rico, The Caribbean, and Parts of Central and South America (Newsfile) -8.26%
08:06PM	Loading…
Sep-27-24 08:06PM	Quantum Biopharma Provides Corporate Update (ACCESSWIRE)
Sep-25-24 09:20AM	Quantum BioPharma to Present at Global Growth and Investment Conference Presented by ArcStone Securities and Investments and Kingswood US (ACCESSWIRE)
Sep-13-24 04:00PM	Quantum BioPharma Closes Private Placement Offering (Newsfile)
Sep-09-24 07:30AM	Quantum Biopharma Signs an Agreement With Ingenu CRO to Conduct a Clinical Study to Observe Disease Progression in Patients With Primary Progressive Multiple Sclerosis (ACCESSWIRE)
Sep-06-24 07:30PM	Quantum Biopharma Receives Nasdaq Notification of Regaining Compliance with Nasdaq's Minimum Bid Price Requirement and Completes Debt Settlements (ACCESSWIRE)
Aug-30-24 10:30AM	Quantum BioPharma Ltd. (QNTM) Announces Key Milestones; Price Target $12.80 (ACCESSWIRE) -8.30%
07:30AM	Quantum Biopharma Announces Celly Nutrition Launches unbuzzd(TM) Grab-and-Go Stick Packs on Amazon.com so you can 'own NOW and what's NEXT' (ACCESSWIRE)
Aug-23-24 07:30PM	Quantum Biopharma Announces Intention to Complete Debt Settlements and Provides Corporate Update (ACCESSWIRE)
Aug-15-24 06:00AM	FSD Pharma Completes Name Change to Quantum BioPharma and 65:1 Consolidation - Trading Under New Ticker Symbol 'QNTM' (Newsfile) -26.93%
Aug-12-24 07:30AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace) -35.05%
Aug-09-24 04:00PM	FSD Pharma Announces Share Consolidation and Name Change (Newsfile) +120.75%
10:51AM	FSD Pharma Is Up 216% Today. What Is Going On With HUGE Stock? (InvestorPlace)
07:30AM	FSD Pharma Provides Update on its Investment in Celly Nutrition Corp. Who Secures Additional Financing to Launch unbuzzd(TM) Stick Packs this Month - Created by a World-Class Pharmaceutical Research & Development Team (ACCESSWIRE)
Jul-25-24 09:20AM	24/7 Market News Publishes Report Covering Functional Beverage Market, Featuring FSD Pharma (Newsfile)
Jul-23-24 03:34PM	FSD Pharma Inc. Announces Results of Annual General and Special Meeting of Shareholders (Newsfile) +10.21%
10:29AM	Loading…
10:29AM	24/7 Market News Publishes Report Covering Biotech Developments, Featuring FSD Pharma (Newsfile)
Jul-04-24 08:00AM	FSD Pharma Files Amended and Restated Material Change Report (Newsfile)
Jun-28-24 05:00PM	FSD Pharma provides Corporate Update (ACCESSWIRE) -15.44%
07:30AM	FSD Pharma, Inc. Wins Final Judgment to Confirm Arbitration Award of $3,059,998 Plus Interest Entered Against Dr. Raza Bokhari, Currently Serving as Chairman and CEO of Medicus Pharma Ltd. (ACCESSWIRE)
Jun-27-24 07:30AM	FSD Pharma Receives Ethics Committee Approval for a Phase-1 Multiple Ascending Doses Clinical Trial for Lucid-21-302 (Lucid-MS) in Australia (ACCESSWIRE) -5.03%
Jun-13-24 07:30AM	FSD Pharma Enters Into an Exclusive Option Agreement With the University of Southern California To Evaluate Novel Dietary Supplement Technology for unbuzzd(TM) and Other Business Applications (ACCESSWIRE) -9.92%
Jun-04-24 07:30AM	FSD Pharma Receives Institutional Review Board Approval to Study the Safety and Efficacy of Unbuzzd(TM) in Acute Alcohol Intoxication (ACCESSWIRE)
Jun-02-24 03:42PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector week of 6/2/24 (Market Exclusive)
May-31-24 07:30AM	FSD Pharma, Inc. Wins Petition to Confirm Arbitration Awards Entered Against Dr. Raza Bokhari Totaling Over $3 Million CAD, Plus Interest (ACCESSWIRE)
May-28-24 08:00AM	FSD Pharma Submits a Clinical Trial Protocol to Study the Safety and Efficacy of Unbuzzd(TM) in Acute Alcohol Intoxication (ACCESSWIRE)
May-24-24 05:15PM	FSD Pharma Provides Corporate Update (ACCESSWIRE)
May-20-24 10:53AM	HUGE Stock Earnings: FSD Pharma Reported Results for Q1 2024 (InvestorPlace) +9.72%
May-16-24 08:00AM	FSD Pharma Provides Update on Celly Nu's New Packaging for unbuzzd(TM) (ACCESSWIRE)
May-07-24 08:30AM	FSD Pharma Submits a Phase-1 Multiple Ascending Doses Clinical Trial Application for Lucid-21-302 (Lucid-MS) for Ethics Committee Review in Australia (ACCESSWIRE)
Apr-30-24 08:33AM	FSD Pharma Signs Agreement with Applied Science and Performance Institute (ASPI) to Conduct a Clinical Trial in the United States to Assess the Safety and Efficacy of unbuzzd(TM) in an Induced State of Alcohol Intoxication (ACCESSWIRE) -6.96%
Apr-25-24 07:47AM	FSD Pharma Provides Update from Celly Nu's Partnership with Six+One for unbuzzd(TM) (ACCESSWIRE)
Apr-22-24 08:00AM	FSD Pharma Provides Another Update on Celly Nu's Anticipated Launch of unbuzzd(TM) (ACCESSWIRE)
Apr-17-24 08:00AM	FSD Pharma Expands Investigative Pipeline to Include Potential Weight Loss and Liver Health Formulations and Products (ACCESSWIRE) -7.80%
Apr-15-24 08:00AM	FSD Pharma Provides Update on its Investment in Celly Nutrition Corp., a Company Launching a Product that can assist in Expediting Alcohol Metabolism and Faster Recovery from Alcohol Consumption (ACCESSWIRE) -12.40%
Apr-07-24 10:55PM	FSD Pharma Inc. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency (Newsfile)
Apr-01-24 10:00PM	FSD Pharma Announces Filing of Year-End 2023 Results (ACCESSWIRE)
Mar-27-24 08:00AM	FSD Pharma Signs the Agreement With iNGENu CRO To Conduct a Clinical Study To Assess the Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 (Lucid-MS) in Healthy Adults (ACCESSWIRE)
Mar-11-24 08:00AM	FSD Pharma Submits a Phase-1b Clinical Trial Application for Ethics Committee for its Proprietary Beverage unbuzzd(TM) (ACCESSWIRE)
Mar-05-24 08:00AM	FSD Pharma Presents Positive Results on First-In-Human Phase-1 study of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 Forum (ACCESSWIRE)
Feb-28-24 08:00AM	FSD Pharma Announces Debt Settlement (ACCESSWIRE)
Feb-26-24 08:00AM	FSD Pharma Signs Agreement With Ingenu CRO to Conduct a Clinical Trial To Determine the Safety and Efficacy Effects of its Proprietary Blend Beverage unbuzzd(TM) (ACCESSWIRE)
Feb-16-24 07:50PM	FSD Pharma Announces US ATM Offering (ACCESSWIRE) +7.17%
Feb-06-24 07:00AM	Court of Appeal Dismisses Motion for Leave to Appeal Brought by Dr. Raza Bokhari, FSD Pharma Awards Total Approximately $3 Million (ACCESSWIRE)
Jan-29-24 04:30PM	FSD Pharma Announces Dr. Sanjiv Chopra is elected to FSD Pharma Board of Directors and Corporate Updates (ACCESSWIRE)
Jan-16-24 07:30AM	Update Provided on GBB Drink Lab, Inc. Litigation and Safety Shot (ACCESSWIRE)
Jan-11-24 01:10PM	GBB Maintains Strong Position in its Ongoing Lawsuit with FSD Pharma After Court Refuses to Dismiss Case (GlobeNewswire) -7.00%
Dec-22-23 07:45PM	FSD Pharma Files Final Base Shelf Prospectus to Replace Expired Base Shelf Prospectus and Form F-3 Registration Statement with the SEC (ACCESSWIRE)
Dec-05-23 09:00AM	FSD Pharma Inc. Announces Closing of Private Placement (ACCESSWIRE)
Nov-30-23 08:30AM	FSD Pharma Inc. and Celly Nutrition Corp. Announce Completion of Plan of Arrangement (ACCESSWIRE)
Nov-28-23 09:00AM	Update Provided on GBB Drink Lab, Inc. Litigation and Safety Shot Previously known as Jupiter Wellness (ACCESSWIRE) -6.35%
Nov-27-23 07:30AM	FSD Pharma Inc. Obtains Final Order for Plan of Arrangement (ACCESSWIRE)
Nov-24-23 07:55AM	Goldman Small Cap Research Publishes New Research Report on FSD Pharma, Inc. (ACCESSWIRE)
Nov-21-23 09:00AM	FSD Pharma Inc. Securityholders Approve Plan of Arrangement with Celly Nutrition Corp. (ACCESSWIRE) +6.30%
Nov-17-23 08:00AM	FSD Pharma Announces Distribution Date for Distribution of Celly Shares Pursuant to Plan of Arrangement (ACCESSWIRE)
Nov-15-23 09:00AM	FSD Pharma Files Supplement to Management Information Circular in Connection with Special Meeting to be Held on November 20, 2023 (ACCESSWIRE) +6.42%
Nov-07-23 11:45AM	FSD Pharma Provides Update on Proposed Dividend Distribution for Shareholders of FSD Pharma to Receive Shares of Celly Nutrition on a One for One Basis (ACCESSWIRE)
Nov-06-23 05:40PM	FSD Pharma Files Preliminary Base Shelf Prospectus to Replace Expired Base Shelf Prospectus (ACCESSWIRE)
Oct-23-23 09:00AM	FSD Pharma Files Management Information Circular for Proposed Arrangement with Celly Nu (ACCESSWIRE)
Oct-05-23 07:30AM	FSD Pharma and Celly Nu Enter Into Arrangement Agreement (ACCESSWIRE)
Oct-04-23 08:35AM	FSD Pharma Wins $2.8 Million Dollar Award Plus Accruing Interest from Dr. Raza Bokhari; Set Aside Motion Brought by Bokhari, Now CEO of Medicus Pharma, Dismissed by the Ontario Superior Court of Justice (ACCESSWIRE)
Sep-22-23 06:00AM	InvestmentPitch Media Video Discusses FSD Pharmas Continued Development of its Exciting New Rapid Detox Drink UNBUZZD, with Video Comments from Kevin Harrington (GlobeNewswire) -8.76%
Sep-18-23 07:30AM	FSD Pharma announces Interim Results from First-in-Human Clinical Trial of Lucid-MS (Lucid-21-302) for Multiple Sclerosis; The Report Shows Compound to be Safe and Well Tolerated (ACCESSWIRE) +6.67%
Sep-13-23 07:30AM	FSD Pharma Announces Analyst Coverage Initiated by Singular Research (ACCESSWIRE)
Aug-25-23 06:16PM	FSD Pharma Rebuts Claims of GBB Drink Lab now acquired by Jupiter Wellness Inc. Trading under the symbol (NASDAQ: JUPW) (Business Wire) +5.04% -5.60%
Aug-15-23 07:30AM	FSD Pharma Selected to Present its Phase 1 Data on Lucid-MS at MSMilan 2023 9th Joint ECTRIMS-ACTRIMS Meeting for October 11-13, 2023 (ACCESSWIRE)
Aug-03-23 06:00AM	InvestmentPitch Media Video Features FSD Pharmas Definitive Agreement Granting Exclusive Rights for Launch of UNBUZZD, a Revolutionary Rapid Alcohol Detoxification Drink (GlobeNewswire)
Aug-02-23 07:30AM	FSD Pharma Signs Definitive Agreement to Launch UNBUZZD, a Revolutionary Rapid Alcohol Detoxification Drink (ACCESSWIRE)
Jul-17-23 05:00PM	Arbitration Panel Finds that Syneos Health (NASDAQ: SYNH) Failed to Use Commercially Reasonable Efforts in Conducting its Trial for FSD 201 (Business Wire)
Jul-10-23 07:30AM	FSD Pharma Retains Christian Attar Law and Team of Experts to Lead Preliminary Investigation of Possible Naked Short Selling and Manipulation in its stock (Business Wire)
Jul-04-23 10:00AM	FSD Pharma Appoints Zeeshan Saeed as Chief Executive Officer, Anthony Durkacz to Serve as Executive Co-Chairman of the Board of Directors (Business Wire)
Jun-30-23 08:30AM	FSD Pharma Inc. Announces Results of Annual General and Special Meeting of Shareholders (Business Wire)
Jun-23-23 06:00AM	InvestmentPitch Media Video Discusses FSD Pharmas Granting of Exclusive Rights to Revolutionary Recreational Alcohol Misuse Technology to Celly Nutrition (GlobeNewswire) -6.38%
Jun-21-23 07:03AM	DR. RAZA BOKHARI, FORMER EXECUTIVE CHAIRMAN AND CEO OF FSD PHARMA, FILES TWO ADDITIONAL CLAIMS AGAINST THE COMPANY SEEKING RELIEF AND MONETARY DAMAGES EXCEEDING $30.2 MILLION (PR Newswire) +6.02%
Jun-20-23 07:30AM	FSD Pharma Announces Agreement to Grant Exclusive Rights to Revolutionary Recreational Alcohol Misuse Technology (Business Wire) +11.76%
May-25-23 07:30AM	FSD Pharma Appoints Former Ontario Minister of Health Doctor Eric Hoskins to Board of Directors (Business Wire)
May-16-23 06:00AM	InvestmentPitch Media Video Discusses FSD Pharmas Cost Award of $2.81 Million from Dr. Raza Bokhari in an Arbitration Settlement (GlobeNewswire) -8.11%
May-12-23 05:00PM	FSD Pharma Announces Receipt of Court Action and Update on Spin-Out and Distribution (Business Wire)
May-11-23 07:30AM	FSD Pharma Awarded $2.81 Million in Cost Awards From Dr. Raza Bokhari (Business Wire)
May-10-23 07:30AM	FSD Pharma Completes Dosing of First Cohort in Phase I Clinical Trial of Lucid-MS, a New Drug Candidate for the Treatment of Multiple Sclerosis: Safety Review Committee Recommends Commencing Dosing of Second Cohort (Business Wire)
May-09-23 07:15AM	Sidoti's Micro-Cap Virtual May Conference (ACCESSWIRE) -7.38%
May-08-23 08:50AM	FSD Pharma to Present at Sidoti Virtual Investor Conference May 10-11 (Business Wire) -6.87%
Apr-17-23 09:00AM	FSD Pharma Achieves Milestone in Completion of Dosing of Sentinel Subjects in First-in-Human Clinical Trial of Lucid-MS (Lucid-21-302) for Multiple Sclerosis (Business Wire) -5.91%
Apr-12-23 09:01AM	IIROC Trade Resumption - HUGE (PR Newswire) +6.25%
08:32AM	IIROC Trading Halt - HUGE (PR Newswire)
08:30AM	FSD Pharma Announces Plan to Spin-Out Subsidiary as Distribution to Shareholders; Shareholder Meeting Scheduled for June 29, 2023 (Business Wire)

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company's three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Quantum BioPharma Ltd

Upgrade your FINVIZ experience